福美坦，一种在非甾体类芳香化酶抑制剂（阿那曲唑和来曲唑）治疗失败后使用的甾体类芳香化酶抑制剂：仍能实现临床获益吗？

Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?

作者信息

Carlini P, Frassoldati A, De Marco S, Casali A, Ruggeri E M, Nardi M, Papaldo P, Fabi A, Paoloni F, Cognetti F

机构信息

Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy.

出版信息

Ann Oncol. 2001 Nov;12(11):1539-43. doi: 10.1023/a:1013180214359.

DOI:10.1023/a:1013180214359

PMID:11822752

Abstract

BACKGROUND

There are few clinical data on the sequential use of aromatase inhibitors (AI). This paper focuses on the relevance of clinical benefit CB (CR + PR + SD > or = 6 months) in postmenopausal metastatic breast cancer (MBC) patients treated with the steroidal aromatase inhibitor (SAI) formestane (FOR). who had already received non-steroidal aromatase inhibitor (nSAI): letrozole (LTZ) or anastrozole (ANZ).

PATIENTS AND METHODS

Twenty postmenopausal women with MBC were analysed in this retrospective two-centre study with the sequence nSAI-FOR. When receiving ANZ, 1 of 11 achieved a complete response and 9 of 11 a stable disease > or = 6 months, and receiving LTZ 1 of 9 achieved a partial response and 4 of 9 a stable disease > or = 6 months. The analysis of the entire population treated with FOR showed an overall CB of 55% (11 of 20) with a median duration of 15 months and median time to progression (TTP) of 6 months.

CONCLUSIONS

Formestane 250 mg once bi-weekly seems to be an attractive alternative third-line hormonal therapy for the treatment of patients with MBC, previously treated with nSAI.

摘要

背景

关于芳香化酶抑制剂（AI）序贯使用的临床数据较少。本文重点关注甾体类芳香化酶抑制剂（SAI）福美坦（FOR）治疗绝经后转移性乳腺癌（MBC）患者的临床获益（CB，完全缓解+部分缓解+疾病稳定≥6个月）的相关性，这些患者之前已接受非甾体类芳香化酶抑制剂（nSAI）来曲唑（LTZ）或阿那曲唑（ANZ）治疗。

患者与方法

在这项回顾性双中心研究中，对20例接受nSAI-FOR序贯治疗的绝经后MBC女性患者进行了分析。接受阿那曲唑治疗时，11例中有1例达到完全缓解，11例中有9例疾病稳定≥6个月；接受来曲唑治疗时，9例中有1例达到部分缓解，9例中有4例疾病稳定≥6个月。对接受福美坦治疗的全部患者的分析显示，总体临床获益率为55%（20例中的11例），中位持续时间为15个月，中位疾病进展时间（TTP）为6个月。